Pharma: Page 23
-
Scott Olson via Getty Images
Lilly boosts outlook on rising Zepbound revenue
Sales of the in-demand obesity drug crested $1 billion in the second quarter as improved Lilly production helped the company fulfill wholesaler backorders.
By Ned Pagliarulo • Aug. 8, 2024 -
Getty Images
Amgen talks obesity drug ‘differentiation’; Servier brain cancer drug approved by FDA
Executives at Amgen had few updates on their drug MariTide, but defended what they see as the once-monthly shot’s competitive profile.
By BioPharma Dive staff • Aug. 7, 2024 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
Courtesy of Novo Nordisk
Novo shares tumble on lower-than-expected obesity drug sales
Quarterly revenue from Ozempic and Wegovy missed Wall Street estimates by about 9%, concerning some analysts and causing a stock sell-off costing the Danish drugmaker tens of billions in market value.
By Kristin Jensen • Aug. 7, 2024 -
Getty Images
Zepbound, Mounjaro back in supply as Lilly resolves shortage
All doses of the in-demand GLP-1 medicines are now available in the U.S., Lilly said ahead of reporting second quarter earnings later this week.
By Ned Pagliarulo • Aug. 5, 2024 -
Courtesy of BMS
Bristol Myers sends TIGIT drug back to Agenus
The decision makes Bristol the latest pharma to pull back on research into a type of cancer immunotherapy that’s drawn significant investment in recent years.
By Ben Fidler • Aug. 5, 2024 -
Adobe Stock / MP Studio
Sponsored by MMITWhy pharma should invest in evidence-based physician education
For years, many manufacturers have assumed that pre-market physician education was not strictly necessary unless their brand was the first to market or had a novel mechanism of action. With the advent of precision medicine, however, ongoing disease state education has become increasingly critical...
By Dr. Shrinal Patel and Carolyn Zele • Aug. 5, 2024 -
Getty Images
Vir retreats from infectious disease; Vertex shelves AATD drugs
The one-time drug developer is pivoting to cancer research. Elsewhere, Neurocrine reported a strong quarter and venBio raised half a billion dollars for biotech investing.
By BioPharma Dive staff • Aug. 2, 2024 -
Getty Images
Obesity drugsLilly obesity drug shows heart benefit in late-stage trial
The drug led to a 38% reduction in the risk of death or complications from a type of heart failure, a finding that compared favorably to available treatments.
By Ben Fidler • Aug. 1, 2024 -
Maddie Meyer via Getty Images
Moderna shares fall amid lower sales outlook for RSV, COVID shots
The biotech cited competitive pressure and “very low” expected sales in Europe for its latest guidance cut, which sent shares down by nearly 20%.
By Delilah Alvarado • Aug. 1, 2024 -
Courtesy of GSK
GSK cuts vaccine forecasts, while predicting faster overall growth
Several factors are slowing U.S. sales of Shingrix, the shingles vaccine that's become one of the British pharma's top sellers.
By Ned Pagliarulo • July 31, 2024 -
Getty Images
Vertex’s pain drug gets speedy FDA review; Keytruda hits a sales milestone
Quarterly sales of Merck’s immunotherapy crested $7 billion for the first time. Elsewhere, Fibrogen is laying off staff and Intellia has a green light to start a new gene editing trial in the U.K.
By BioPharma Dive staff • July 31, 2024 -
Courtesy of Merck & Co.
Merck shares slide as Gardasil sales drop in China
The unexpected disclosure in Merck’s second quarter earnings prompted an investor sell-off that some analysts said might be overblown.
By Kristin Jensen • July 31, 2024 -
Getty Images
Pfizer quits Duchenne gene therapy, lays off staff following study setback
The company is letting go of 150 staffers alongside a decision to officially terminate the high-profile program, which was acquired in 2016.
By Ben Fidler • July 30, 2024 -
Courtesy of GSK
GSK leans on Flagship for help finding new drugs, vaccines
The deal resembles recent Flagship alliances with Pfizer and Novo Nordisk, allowing the British pharma to comb through the company creator’s portfolio to unearth up to 10 therapies.
By Gwendolyn Wu • July 29, 2024 -
Courtesy of Boehringer Ingelheim
Boehringer adds to cancer drug pipeline with deal for startup Nerio
The pharma company will pay up to $1.3 billion to acquire San Diego-based Nerio and its research into novel immune checkpoint inhibitors.
By Ned Pagliarulo • July 29, 2024 -
Drew Angerer via Getty Images
Bristol Myers’ beat completes strong week of pharma earnings
All five large pharmaceutical companies that reported earnings last week raised either their profit or revenue guidance for the year.
By Ned Pagliarulo • July 26, 2024 -
Getty Images
Two biotechs cut staff; AbbVie weathers biosimilar threat
Glycomimetics and Cue Biopharma both revealed layoffs. Elsewhere, AbbVie’s earnings impressed Wall Street and an FDA panel recommended changing testing requirements for some lung cancer drugs.
By BioPharma Dive staff • July 26, 2024 -
Courtesy of Roche
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
CEO Thomas Schinecker claimed the company has “many opportunities” to stand out in the competitive field, and can get to market “much faster” than investors expect.
By Ben Fidler • July 25, 2024 -
Courtesy of Sanofi
Sanofi’s immunology bet starts to pay off
Some analysts described Sanofi’s pipeline of immune system therapies, which includes more than half a dozen drugs in mid- to late-stage testing, as “underappreciated” by investors.
By Jacob Bell • July 25, 2024 -
Getty Images
Pfizer says hemophilia gene therapy meets late-stage study goal
While the study results were positive, questions remain about the longer-term potential of hemophilia treatments like Pfizer’s.
By Kristin Jensen • July 24, 2024 -
Getty Images
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
The Swiss pharma is paying Dren Bio $150 million to partner on “targeted myeloid engagers.” Elsewhere, Geron is losing its commercial chief and Biovectra will sell to Agilent for $925 million.
By BioPharma Dive staff • July 24, 2024 -
Kena Betancur via Getty Images
Merck claims late-stage study success for RSV antibody
The drug, a rival to Sanofi and AstraZeneca’s fast-selling Beyfortus, met its main goals in a Phase 3 trial. But undisclosed study results leave its full potential unclear.
By Ben Fidler • Updated July 23, 2024 -
Mario Tama via Getty Images
J&J seeks expanded approval for antidepressant Spravato
The company is seeking a monotherapy approval for Spravato, sales of which have climbed in recent quarters.
By Delilah Alvarado • July 22, 2024 -
shutterstock.com/TippaPatt
Sponsored by VeradigmClinical data registries: Transforming the future of medical research
Clinical data registries have become invaluable for generating unique insights for life sciences. Read on to learn more.
By Amanda Cohen, MPH • July 22, 2024 -
Anthony Kwan / Stringer via Getty Images
Global tech outage hits US hospitals
At least 11 health systems were experiencing issues Friday after an update by cybersecurity firm CrowdStrike went awry.
By Susanna Vogel • Updated July 19, 2024
Previous
